hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
=== Magnetic confinement fusion === In fusion devices, such as tokamaks and stellarators, ICRH antennas are installed in the machine vessel to heat the plasma using radio waves with frequencies in the range of the ion cyclotron resonance. ICRH provides localized heating of ions in fusion plasmas, which can generate a large population of energetic particles typically inaccessible with other heating methods (such as electron cyclotron resonance heating or neutral beam injection). The confinement properties of fast ions in plasma is a major research topic in fusion plasma physics.
== Diagnosis == The diagnosis of MBS is heavily dependent on the presentation and histopathology of its tumors. Of particular importance, the presence of pseudo-lipoblasts in a myxoid sarcoma-like background is an extremely strong indicator that the tumor is a MFS. and tumors with a myxofibrosarcoma-like histopathology that initiate in the retroperitoneum, abdominal cavity, or pelvis are nearly always dedifferentiated liposarcomas. Magnetic resonance imaging (MRI) has been helpful in diagnosing MBS. On T2-weighted MRI, 81% of MFS tumors give a tail sign, i.e. a multidirectional signal spreading away from the main mass along a facial plane (i.e. a line or band of connective tissue). Among all myxoid-predominant tissue lesions, this MRI method diagnoses MBS with a specificity of 79% to 90%. This MRI finding is also extremely valuable for gauging the extent and depth of surgery needed to completely remove MBS tumors.
MOFs must be synthesized on the nanoscale so as not to affect the target's normal interactions or behavior The absorbance and emission wavelengths must occur in regions with minimal overlap from sample autofluorescence, other absorbing species, and maximum tissue penetration. Regarding the first point, nanoscale MOF (NMOF) synthesis has been mentioned in an earlier section. The latter obstacle addresses the limitation of the antenna effect. Smaller linkers tend to improve MOF stability, but have higher energy absorptions, predominantly in the ultraviolet (UV) and high-energy visible regions. A design strategy for MOFs with redshifted absorption properties has been accomplished by using large, chromophoric linkers. These linkers are often composed of polyaromatic species, leading to large pore sizes and thus decreased stability. To circumvent the use of large linkers, other methods are required to redshift the absorbance of the MOF so lower energy excitation sources can be used. Post-synthetic modification (PSM) is one promising strategy. Luo et al. introduced a new family of lanthanide MOFs with functionalized organic linkers. The MOFs, deemed MOF-1114, MOF-1115, MOF-1130, and MOF-1131, are composed of octahedral SBUs bridged by amino functionalized dicarboxylate linkers. The amino groups on the linkers served as sites for covalent PSM reactions with either salicylaldehyde or 3-hydroxynaphthalene-2-carboxaldehyde. Both of these reactions extend the π-conjugation of the linker, causing a redshift in the absorbance wavelength from 450 nm to 650 nm.
Sources: en.wikipedia.org
Lulu Mall Hyderabad is a shopping mall located in Hyderabad, the capital city of Telangana, India. It is the first lulu mall in the state of Telangana, located in Kukatpally. The mall was inaugurated in September 2023 and houses shops for both domestic and international brands as well as a multi-cuisine food court, a theatre, and other amenities. The estimated cost for this project was more than ₹300 crore. The property is owned and managed by Abu Dhabi based LuLu Group International.
== Signs and symptoms == The only sign of vitiligo is the presence of pale, patchy areas of depigmented skin, which tend to occur on the extremities. Some people may experience itching before a new patch appears. The patches are initially small, but often grow and change shape. When skin lesions occur, they are most prominent on the face, hands, and wrists. The loss of skin pigmentation is particularly noticeable around body orifices, such as the mouth, eyes, nostrils, genitalia and umbilicus. Some lesions have increased skin pigment around the edges. Additionally, the hair of affected areas can turn white or gray due to the loss of melanin. Those affected by vitiligo who are stigmatized for their condition may experience depression and similar mood disorders. Vitiligo also appears in other mammals, being conspicuous for instance on Arabian horses.
=== CITES and species risk === According to the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), products made from endangered species can be legally traded after certification. CITES lists the Nile crocodile under Appendix II which means a species that is not necessarily currently endangered, but which is in danger of becoming extinct unless trade in specimens is strictly regulated to prevent uses that threaten its survival. The collection, processing, domestic trading, and exporting of all crocodile products must be controlled. Over catching of this animal has led to the decline of this species in wild populations. Efforts are made to preserve the existing habitat of this species. Crocodiles have been bred in farms since the early twentieth century, where Thai crocodile farming industry is currently the largest in the world. Breeding this animal under captivity is a developing industry in some parts of the world.
Sources: en.wikipedia.org
=== Barley straw === Barley straw, in the United Kingdom, is placed in mesh bags and floated in fish ponds or water gardens to help reduce algal growth without harming pond plants and animals. Barley straw has not been approved by the United States Environmental Protection Agency (EPA) for use as a pesticide and its effectiveness as an algaecide in ponds has produced mixed results during university testing in the United States and the United Kingdom. It is unclear how straw actually works.
Highland Council announces that Inverness's Hogmanay celebration will not take place in 2024–25 due to capacity and rising costs. 23 August – Edinburgh City Council votes to introduce a temporary fireworks ban around Bonfire Night in the city's Niddrie, Balerno, Seafield and Calton Hill districts, becoming the first Scottish council to implement such a ban. 25 August – BBC Scotland News reports that Scotland's local authorities are to divert money used to restore nature projects to pay for wage increases. 26 August – ASLEF suspends planned strike action for ScotRail drivers following a new pay offer, and will ballot its members on the offer. The Scottish Government confirms it will suspend the Connecting Scotland programme which provides iPads and laptops to people who are "digitally excluded" in order to pay for council pay rises. 28 August – Justice Secretary Angela Constance confirms that around 470 prisoners have been released under emergency provisions to release prisoners early from their sentences. 30 August – Cheyenne Naeb, an American philosophy student at the University of Dundee, who pushed a female member of railway staff in front of a stationary train at Glasgow Queen Street railway station in February 2023 after missing his train, is sentenced to 20 months in prison at Glasgow Sheriff Court. During a closed-door session at the SNP Party Conference, leader John Swinney tells delegates the party's losses at the election occurred because it spent too much time focusing on the "process of independence".
On 15 March 2024 cyclist Christos Volikakis was informed of an Adverse Analytical Finding on a re-analysis of a sample from the 2016 Rio Olympics. The athlete has since requested an analysis of the B sample. In 2015, the quarterback of the Florida Gators, Will Grier, was suspended for testing positive for LGD-4033, a claim that the University of Florida denies. In 2017, Joakim Noah was banned for twenty games by the NBA for testing positive for LGD-4033. In 2019, Australian swimmer Shayna Jack tested positive for LGD-4033. She denies knowingly taking the substance. In August 2019, it came to light that Canadian sprint canoeist Laurence Vincent Lapointe tested positive for LGD-4033; the athlete denies knowingly taking a forbidden substance that resulted in her suspension from competition. The athlete remarked that the National Team Training Centre purchased nutritional supplements for its athletes and denied buying or taking nutritional supplements on her own. On 27 January 2020 she was cleared of all charges. The substance was found in her results because of an exchange of bodily fluids with her boyfriend, who took LGD-4033. In January 2020, Chilean ATP tennis singles competitor Nicolás Jarry tested positive for both LGD-4033 and stanozolol. He protested at the time that the multi-vitamins from Brazil that he took on the advice of an unnamed doctor were contaminated. On 3 September 2022, sprinter Nzubechi Grace Nwokocha was provisionally suspended for the use of banned substances enobosarm and LGD-4033 by the Athletics Integrity Unit (AIU).
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.